Current Report Filing (8-k)
January 18 2017 - 5:03PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported):
January 17, 2017
ENDONOVO
THERAPEUTICS, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
333-176954
|
|
45-2552528
|
(State
or other jurisdiction
|
|
(Commission
|
|
(IRS
Employer
|
of
incorporation)
|
|
File
Number)
|
|
Identification
No.)
|
6320
Canoga Avenue, 15
th
Floor
Woodland
Hills, CA 91367
(Address
of principal executive office)(Zip Code)
Registrant’s
telephone number, including area code:
(800) 489-4774
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[
]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item
3.03 Material Modification to Rights of Security Holders.
On
January 17, 2017, we filed a certificate of amendment to our certificate of incorporation which increased the number of shares
of shares of common stock that we are authorized to issue from 250,000,000 shares to 500,000,000 shares (the “Amendment”).
The Amendment was approved by our board of directors and by the majority in voting interest of our shareholders. We advised our
shareholders through an Information Statement under regulation 14C under the Securities and Exchange Act of 1934, as amended,
that we intended to file the Amendment.
Item
9.01 Financial Statements and Exhibits.
|
(a)
|
Financial
Statements -None
|
|
|
|
|
(b)
|
Exhibits
|
|
|
|
|
|
3.1
Certificate of Amendment filed January 17, 2017
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Dated:
January 18, 2017
|
ENDONOVO
THERAPEUTICS, INC.
|
|
|
|
By:
|
/s/
Alan Collier
|
|
|
Alan
Collier
|
|
|
Chief
Executive Officer
|